Publications by authors named "Merce Pont"

Claim this Profile
I
Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa.
Irene Jover, Maria C Ramos, María José Escámez, Estrella Lozoya, José R Tormo, Mercè Pont

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of propylene glycol on the skin penetration of drugs.
Victor Carrer, Cristina Alonso, Mercè Pont, Miriam Zanuy, Mònica Córdoba

Arch Dermatol Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of the skin permeability of topical drugs using in silico and in vitro models.
Cristina Alonso, Víctor Carrer, Sonia Espinosa, Miriam Zanuy, Mònica Córdoba, Mercè Pont

Eur J Pharm Sci· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita.
Hiroshi Koga, Anika Kasprick, Rosa López, Mariona Aulí, Mercè Pont

Front Immunol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice.
Gema Tarrasón, Mariona Aulí, Sanam Mustafa, Vladislav Dolgachev, Maria Teresa Domènech, Mercè Pont

Int Immunopharmacol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist.
Paul Eastwood, Cristina Esteve, Jacob González, Silvia Fonquerna, Josep Aiguadé, Mercè Pont

ACS Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist.
Bernat Vidal, Arsenio Nueda, Cristina Esteve, Teresa Domenech, Sonia Benito, Mercè Pont

J Med Chem· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis